HMG CoA reductase inhibitor associated myositis and autoimmune hepatitis (Letter)

No Thumbnail Available
File version
Author(s)
Palamuthusingam, Dharmenaan
Mantha, Murty
Dheda, Shyam
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
2017
Size
File type(s)
Location
License
Abstract

The use of statins is increasing. Although both autoimmune hepatitis and statin related myopathy have been reported to occur following commencement of statin therapy, they have not been reported to occur in the same patient. We present such a case and her clinical course. Stains are widely prescribed in the chronic kidney disease (CKD) population. They have been known to unmask or initiate immune-mediated disease

Journal Title

Internal Medicine Journal

Conference Title
Book Title
Edition
Volume

47

Issue

10

Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject

Cardiovascular medicine and haematology

Clinical sciences

Science & Technology

Life Sciences & Biomedicine

Medicine, General & Internal

General & Internal Medicine

STATINS

Persistent link to this record
Citation

Palamuthusingam, D; Mantha, M; Dheda, S, HMG CoA reductase inhibitor associated myositis and autoimmune hepatitis, Internal Medicine Journal, 2017, 47 (10), pp. 1213-1215

Collections